Chief Executive Officer, Emmer Capital Partners Limited

Manishi Raychaudhuri

Chief Executive Officer

Emmer Capital Partners Limited

Emmer Capital Partners is an Asia Pacific focused financial advisory firm engaging in strategic financial asset allocation advice, bespoke thematic research and advising early-stage companies and connecting them to investors. Emmer Capital provides macro-economic and multi-asset investment strategy inputs to institutions, family offices, private wealth managers, private equity, and corporate boards directly and through independent research platforms. Emmer Capital also advises a wide range of startup companies on fund raising and business strategy. Emmer Capital's active engagement with the print and electronic media reaches a broad spectrum of investors across the globe.

Cross Asset Strategy

<ul>
<li>July’s $17.28 bn inflow through Southbound was almost triple of that of the May low ($5.85bn). The flows are now on track to recovering to the March-April peak of $20-22bn.</li>
<li>Investors continue buying dividend plays (CCB), sharp decliners (Meituan), policy beneficiaries (SMIC). Kuaishou and Alibaba were bought after being sold recently. Biotechnology (Innovent, Akeso) and insurance (ChinaLife) are new favorites.</li>
<li>Expensive consumers and consumer proxies (Pop Mart, Tencent, Xiaomi) continue to be sold. Last three months selling in Xiaomi and Tencent have almost wiped out their cumulative 12 month's buying.</li>
</ul>


July’s $17.28 bn inflow through Southbound was almost triple of that of the May low ($5.85bn). The flows are now on track to recovering to the March-April peak of $20-22bn.
Investors continue buying dividend plays (CCB), sharp decliners (Meituan), policy beneficiaries (SMIC). Kuaishou and Alibaba were bought after being sold recently. Biotechnology (Innovent, Akeso) and insurance (ChinaLife) are new favorites.
Expensive consumers and consumer proxies (Pop Mart, Tencent, Xiaomi) continue to be sold. Last three months selling in Xiaomi and Tencent have almost wiped out their cumulative 12 month's buying.


Asian Equity: Southbound Monthly- July Boom; New Darlings: Insurance, Biotech; Pricey Consumers Sold

Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

Shenton Research

Shenton Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Equity Capital Markets

ASR Microelectronics / Equity Capital Markets

<ul>
<li>ASR Microelectronics, a fabless designer of cellular connectivity chips and AI SoCs, is seeking an A+H listing. MS and Haitong are the joint sponsors.</li>
<li>We look at the company's three segments: wireless connectivity chips, smart device SoCs and custom ASIC solutions.</li>
<li>We discuss our preliminary thoughts on the company's valuation based on the A-H premium.</li>
</ul>


ASR Microelectronics, a fabless designer of cellular connectivity chips and AI SoCs, is seeking an A+H listing. MS and Haitong are the joint sponsors.
We look at the company's three segments: wireless connectivity chips, smart device SoCs and custom ASIC solutions.
We discuss our preliminary thoughts on the company's valuation based on the A-H premium.


ASR Microelectronics (翱捷科技) A+H Pre-IPO: Early Thoughts

Dealing, Product Financing and Custody Services, Tickrs

Tickrs

Dealing, Product Financing and Custody Services

Tickrs Financial Singapore Pte Ltd (TFS) obtained Capital Markets Services (CMS) License from the Monetary Authority of Singapore (MAS) in 2022. Product offering include stock trading services across 10 global markets, futures trading, fixed income and wealth management products offering.

Thematic (Sector/Industry)

<ul><li>Positives • Policy Tailwind: Strong government backing as part of China's tech independence roadmap.</li><li>• Capex Expansion: Multi-node roadmap with increasing domestic orders.</li><li>• Regional Proxy: For investors seeking chip exposure without investing directly in US or Taiwanese stocks.</li></ul>

Positives • Policy Tailwind: Strong government backing as part of China's tech independence roadmap.• Capex Expansion: Multi-node roadmap with increasing domestic orders.• Regional Proxy: For investors seeking chip exposure without investing directly in US or Taiwanese stocks.

Market Insights : Six Newly Listed SGX SDRs

HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

RoboTechnik Intelligent Technology / Equity Capital Markets

RoboTechnik Intelligent Technology (RBTK HK)

<ul>
<li>RoboTechnik's fundamentals are currently in a stage of "strong story but weak profits". The SiPh equipment sector has sufficient market appeal, but the profit scale is still small</li>
<li>Based on 26H1 explosive growth of optoelectronics business, significant jump in profitability in 26Q2, and the 2.452bn yuan in-hand orders for optoelectronics, the forecast needs to be systematically revised upwards</li>
<li>Considering the growth potential of RoboTechnik (with a projected CAGR of 100+% in net profits from 2026 to 2028), 35-45x P/E based on 2027 forecast could be a comfortable range</li>
</ul>


RoboTechnik's fundamentals are currently in a stage of "strong story but weak profits". The SiPh equipment sector has sufficient market appeal, but the profit scale is still small
Based on 26H1 explosive growth of optoelectronics business, significant jump in profitability in 26Q2, and the 2.452bn yuan in-hand orders for optoelectronics, the forecast needs to be systematically revised upwards
Considering the growth potential of RoboTechnik (with a projected CAGR of 100+% in net profits from 2026 to 2028), 35-45x P/E based on 2027 forecast could be a comfortable range


Pre-IPO RoboTechnik Intelligent Technology (PHIP Updates) - Some Points Worth the Attention

Quantitative Analysis

<ul>
<li>We analyze the weekly Hong Kong Connect flows with our data engine for holding position as of September 18th.</li>
<li>The top stocks by inflows and outflows were tabulated for all market, HSCEI, mid cap and s/mid cap groups.</li>
<li>We highlight flows for Knowledge Atlas, AIA, Innovent Bio, Beone Medicines, Zj Innolight, Hua Hong Semi, Cspc Pharma, Smic, Yofc, Akeso.</li>
</ul>


We analyze the weekly Hong Kong Connect flows with our data engine for holding position as of September 18th.
The top stocks by inflows and outflows were tabulated for all market, HSCEI, mid cap and s/mid cap groups.
We highlight flows for Knowledge Atlas, AIA, Innovent Bio, Beone Medicines, Zj Innolight, Hua Hong Semi, Cspc Pharma, Smic, Yofc, Akeso.


HK Connect Flows Weekly (Sep 18th): Knowledge Atlas, AIA, Innovent Bio, Beone Medicines, Cspc Pharma

China

Semiconductor Manufacturing International Corporation operates as a semiconductor foundry. The Company provides integrated circuit foundry and technology services including the testing, development, design, manufacturing, packaging, and sale of integrated circuits. Semiconductor Manufacturing International offers its products and services around the world.

SMIC (Semiconductor Manufacturing International Corp) (688981 CH)

SMIC (Semiconductor Manufacturing International Corp)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

SMIC (Semiconductor Manufacturing International Corp) (688981 CH)

Asian Equity: Southbound Monthly- July Boom; New Darlings: Insurance, Biotech; Pricey Consumers Sold

July Southbound flow nearly tripled from May's low, on track to reach Mar-Apr peak. Investors like dividend plays, policy beneficiaries & recently...

Manishi Raychaudhuri

ASR Microelectronics (翱捷科技) A+H Pre-IPO: Early Thoughts

ASR Microelectronics is seeking an A+H listing. In this note, we look at the company's business, its industry context and provide our early...

Ke Yan, CFA, FRM

Market Insights : Six Newly Listed SGX SDRs

Positives • Policy Tailwind: Strong government backing as part of China's tech independence roadmap. • Capex Expansion: Multi-node roadmap with...

Tickrs

Pre-IPO RoboTechnik Intelligent Technology (PHIP Updates) - Some Points Worth the Attention

RoboTechnik's IPO pricing is ≦HK$436, with MV of ≦HK$78.3bn. Based on 2027 forecast, PE is 122x, higher than our estimate and peers (ASMPT/SMIC),...

Xinyao (Criss) Wang

HK Connect Flows Weekly (Sep 18th): Knowledge Atlas, AIA, Innovent Bio, Beone Medicines, Cspc Pharma

We analyzed southbound Hong Kong connect flows in the past week and highlighted flows for Knowledge Atlas (2513 HK), AIA (1299 HK), Innovent Bio...

Ke Yan, CFA, FRM

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Asian Equity: Southbound Monthly- July Boom; New Darlings: Insurance, Biotech; Pricey Consumers Sold

July ​Southbound flow nearly tripled from May's low, on track to reach Mar-Apr peak. Investors like dividend plays, policy beneficiaries & recently...

Manishi Raychaudhuri

ASR Microelectronics (翱捷科技) A+H Pre-IPO: Early Thoughts

ASR Microelectronics is seeking an A+H listing. In this note, we look at the company's business, its industry context and provide our early...

Ke Yan, CFA, FRM

Market Insights : Six Newly Listed SGX SDRs

Positives • Policy Tailwind: Strong government backing as part of China's tech independence roadmap. • Capex Expansion: Multi-node roadmap with...

Tickrs

Pre-IPO RoboTechnik Intelligent Technology (PHIP Updates) - Some Points Worth the Attention

RoboTechnik's IPO pricing is ≦HK$436, with MV of ≦HK$78.3bn. Based on 2027 forecast, PE is 122x, higher than our estimate and peers (ASMPT/SMIC),...

Xinyao (Criss) Wang

HK Connect Flows Weekly (Sep 18th): Knowledge Atlas, AIA, Innovent Bio, Beone Medicines, Cspc Pharma

We analyzed southbound Hong Kong connect flows in the past week and highlighted flows for Knowledge Atlas (2513 HK), AIA (1299 HK), Innovent Bio...

Ke Yan, CFA, FRM

July Southbound flow nearly tripled from May's low, on track to reach Mar-Apr peak. Investors like dividend plays, policy beneficiaries & recently...